It's known that at diagnosis of DMI there is still some reserve of pancreatic B-cells. and that its preservation is important to reduce the chronic complications of the disease. Objective- Evaluate nicotinamide action upon insulin secretion in recent-onset DML We analysed 14 patients, diagnosed within 6 weeks, with chronological age=9 Sv (2.3-2.2v). 9F and 5 M. in a double-blind prospective study. They were divided in 2 groups to receive NCT. 40 mg kg/d. (Group 1) or Placebo (Group 2). We analysed HbA1 levels ([Illegible Text] cromatography - nv=3.6-5.3″,)and C-peptide months (RIE-kit DPC) basai and after stimulation with Sustacal, before NCT introdution and each three months during the first year. Insulin dose was also assessed (units per kilo - U/Kg). Results. -C-petide. HbA1 and U/kg evolution during the first year after diagnosis: Table

Table 1
Full size table

Discussion-C-peptide levels remain stable during the first year of follow-up. Even though in this group of patients (young with low C-peptide levels at diagnosis). NCT had no action in insulin secretion. Despite the fact that no changes occured related to C-peptide and insulin doses. HbA1 level fell significantly in the group of NCT. These data suggest as found by other authors that NCT may have some action over peripheric insulin sensitivity.